dyskinesias

Halopemide is a potent inhibitor of PLD (IC50 = 220 and 310 nM for human PLD1 and PLD2). Halopemid is an antagonist of dopamine receptors. Halopemid can be used in psychotropic research.

Piribedil (Trivastan) is a dopamine D2 agonist, used in the treatment of Parkinson's disease.

Mavoglurant (AFQ056) is a potent, selective, non-competitive, and orally active metabotropic glutamate receptor 5 (mGluR5) antagonist with an IC50 of 30 nM, demonstrating greater than 300-fold selectivity over 238 tested targets, and it is widely applied in research on Fragile X syndrome and L-dopa-induced dyskinesias in Parkinson’s disease, while Mavoglurant incorporated alkyne functional group, which enables copper-catalyzed azide–alkyne cycloaddition click chemistry, facilitating target engagement and molecular tracking studies.